IOVA Earnings & Financial Statements
Iovance Biotherapeutics, Inc.
$13.31
+$0.40(+3.06%)
59
Overall
60
Value
75
Tech
42
Quality
Market Cap
$5.85B
Volume
14.69M
52W Range
$1.76 - $15.30
Target Price
$13.09
IOVA earnings and financial statements: Iovance Biotherapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
IOVA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $263.50M | $164.07M | $1.19M | - | - |
| Cost of revenue | $173.18M | $93.25M | $10.76M | - | - |
| Operating income | -$403.36M | -$395.28M | -$460.56M | -$398.88M | -$342.70M |
| EBITDA | -$345.75M | -$326.91M | -$414.43M | -$374.77M | -$328.72M |
| Net income | -$391.00M | -$372.18M | -$444.04M | -$395.89M | -$342.25M |
| EPS (diluted) | $-1.09 | $-1.28 | $-1.89 | $-2.49 | $-2.23 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $913.17M | $910.43M | $780.35M | $663.98M | $777.33M |
| Total liabilities | $214.59M | $200.02M | $195.74M | $164.34M | $155.67M |
| Shareholders’ equity | $698.58M | $710.40M | $584.61M | $499.64M | $621.66M |
| Cash and equivalents | $163.08M | $115.69M | $114.89M | $231.73M | $78.23M |
| Long-term debt | $44.40M | $45.37M | $68.08M | $72.86M | $66.47M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$302.40M | -$352.98M | -$361.82M | -$292.76M | -$227.94M |
| Capital expenditure | -$33.84M | -$11.07M | -$22.29M | -$20.43M | -$37.57M |
| Free cash flow | -$336.24M | -$364.05M | -$384.11M | -$313.18M | -$265.51M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IOVA | $13.31 | +3.1% | 14.69M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Iovance Biotherapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW